Erin Doty

743 total citations
30 papers, 531 citations indexed

About

Erin Doty is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Surgery. According to data from OpenAlex, Erin Doty has authored 30 papers receiving a total of 531 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Psychiatry and Mental health, 8 papers in Pathology and Forensic Medicine and 6 papers in Surgery. Recurrent topics in Erin Doty's work include Migraine and Headache Studies (20 papers), Trigeminal Neuralgia and Treatments (7 papers) and Cardiovascular Syncope and Autonomic Disorders (6 papers). Erin Doty is often cited by papers focused on Migraine and Headache Studies (20 papers), Trigeminal Neuralgia and Treatments (7 papers) and Cardiovascular Syncope and Autonomic Disorders (6 papers). Erin Doty collaborates with scholars based in United States, Denmark and United Kingdom. Erin Doty's co-authors include John H. Krege, Eric Pearlman, Paul H. Berg, Ellen B. Dennehy, Sheena K. Aurora, Sherie A. Dowsett, Helen Hochstetler, Dustin Ruff, Emily Liffick and Robert E. Shapiro and has published in prestigious journals such as Neurology, Journal of Alzheimer s Disease and Alzheimer s & Dementia.

In The Last Decade

Erin Doty

29 papers receiving 512 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erin Doty United States 13 479 324 181 78 43 30 531
Mark A. Louter Netherlands 8 443 0.9× 229 0.7× 164 0.9× 32 0.4× 56 1.3× 11 486
Ilaria Frattale Italy 14 521 1.1× 347 1.1× 181 1.0× 54 0.7× 31 0.7× 35 605
Angelo Camporeale United States 11 383 0.8× 236 0.7× 109 0.6× 50 0.6× 25 0.6× 16 470
J. Pfeil Germany 8 397 0.8× 254 0.8× 159 0.9× 35 0.4× 24 0.6× 9 410
K. Solbach Germany 6 311 0.6× 188 0.6× 106 0.6× 38 0.5× 23 0.5× 10 403
Willebrordus P. J. van Oosterhout Netherlands 10 417 0.9× 183 0.6× 153 0.8× 26 0.3× 56 1.3× 15 475
Fernando Kowacs Brazil 10 339 0.7× 194 0.6× 121 0.7× 31 0.4× 20 0.5× 22 409
Katharina Kamm Germany 10 518 1.1× 320 1.0× 195 1.1× 42 0.5× 27 0.6× 26 640
Osman Özgür Yalın Türkiye 12 330 0.7× 127 0.4× 116 0.6× 53 0.7× 25 0.6× 22 436

Countries citing papers authored by Erin Doty

Since Specialization
Citations

This map shows the geographic impact of Erin Doty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erin Doty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erin Doty more than expected).

Fields of papers citing papers by Erin Doty

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erin Doty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erin Doty. The network helps show where Erin Doty may publish in the future.

Co-authorship network of co-authors of Erin Doty

This figure shows the co-authorship network connecting the top 25 collaborators of Erin Doty. A scholar is included among the top collaborators of Erin Doty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erin Doty. Erin Doty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Boustani, Malaz, Erin Doty, Louis P. Garrison, et al.. (2024). Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer’s Disease in the United States. Neurology and Therapy. 13(6). 1641–1659. 2 indexed citations
2.
Jack, Clifford R., Ana Graf, Samantha C. Burnham, et al.. (2024). Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice. Alzheimer s & Dementia Translational Research & Clinical Interventions. 10(4). e70013–e70013. 3 indexed citations
3.
Blumenfeld, Andrew, et al.. (2023). Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience. Frontiers in Neurology. 14. 3 indexed citations
4.
Boustani, Malaz, Erin Doty, Louis P. Garrison, et al.. (2022). Assessing the Cost-effectiveness of a Hypothetical Disease-modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease. Clinical Therapeutics. 44(11). 1449–1462. 9 indexed citations
5.
6.
Chandler, Julie, Wenyu Ye, Joseph A. Johnston, Xiaojuan Mi, & Erin Doty. (2022). Potential Savings in Caregiver Time and Societal Costs Associated with Slowing Disease Progression over 36 months in Patients with Early Alzheimer’s Disease: Findings from GERAS‐US. Alzheimer s & Dementia. 18(S11). 3 indexed citations
7.
8.
Vargas, Bert B., Delphine Magis, Erin Doty, et al.. (2020). Assessment to Identify Predictors of 2-Hour Pain Freedom among Patients Enrolled in 2 Phase 3 Studies of Lasmiditan for Acute Treatment of Migraine (1763). Neurology. 94(15_supplement). 1 indexed citations
9.
Smith, Timothy R., John H. Krege, Suchitrita S. Rathmann, et al.. (2020). Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies. Neurology and Therapy. 9(2). 459–471. 9 indexed citations
10.
Doty, Erin, John H. Krege, Gerhardt Pohl, et al.. (2020). Pain Freedom at 2 to 8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant. Headache The Journal of Head and Face Pain. 60(8). 1793–1796. 6 indexed citations
11.
Lipton, Richard B., Li Shen Loo, Andre B. Araujo, et al.. (2020). Migraine and Functional Impairment Associated with Driving: Results of the OVERCOME Study (1638). Neurology. 94(15_supplement). 1 indexed citations
12.
Dodick, David W., Erin Doty, Sheena K. Aurora, et al.. (2020). Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia. 41(3). 340–352. 73 indexed citations
13.
Shapiro, Robert E., Helen Hochstetler, Ellen B. Dennehy, et al.. (2019). Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. The Journal of Headache and Pain. 20(1). 90–90. 66 indexed citations
14.
15.
Ashina, Messoud, Raghavendra Vasudeva, Louise Lombard, et al.. (2019). Onset of Efficacy Following Oral Treatment with Lasmiditan for the Acute Treatment of Migraine (S17.007). Neurology. 92(15_supplement). 1 indexed citations
16.
Krege, John H., Paul Rizzoli, Emily Liffick, et al.. (2019). Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN. Cephalalgia. 39(8). 957–966. 51 indexed citations
17.
18.
Ashina, Messoud, Raghavendra Vasudeva, Louise Lombard, et al.. (2019). Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double‐Blind Placebo‐Controlled Phase 3 Clinical Studies. Headache The Journal of Head and Face Pain. 59(10). 1788–1801. 30 indexed citations
19.
Krege, John H., et al.. (2019). Safety Findings from the Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan for Acute Treatment of Migraine (P1.10-009). Neurology. 92(15_supplement). 2 indexed citations
20.
Leonard, Christiana M., et al.. (2001). Working memory deficits in schizophrenia are not necessarily specific or associated with MRI-based estimates of area 46 volumes. Psychiatry Research Neuroimaging. 108(3). 187–209. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark A. Louter Breakdown of academic impact, for papers by Ilaria Frattale Breakdown of academic impact, for papers by Angelo Camporeale Breakdown of academic impact, for papers by J. Pfeil Breakdown of academic impact, for papers by K. Solbach Breakdown of academic impact, for papers by Willebrordus P. J. van Oosterhout Breakdown of academic impact, for papers by Fernando Kowacs Breakdown of academic impact, for papers by Katharina Kamm Breakdown of academic impact, for papers by Osman Özgür Yalın
Rankless by CCL
2026